

February 7, 2005

Fujisawa obtains the worldwide rights on antipsychotic agent from Carlsson Research

Japan, February 7, 2005 – Fujisawa Pharmaceutical Co., Ltd. today announced that it has concluded a licensing agreement with A. Carlsson Research AB, whereby Fujisawa has obtained exclusive rights to develop, manufacture and market ACR-16, a novel antipsychotic agent, in all countries in the world. Financial terms are not disclosed.

ACR-16 represents a novel principle for the treatment of schizophrenia, “dopaminergic stabilization”, which can either enhance or counteract effects of dopamine in the central nerves system which is involved in pathophysiology of schizophrenia and other neuropsychiatric disorders. The dopaminergic stabilization properties of ACR-16 also make it a candidate for the treatment of other neuropsychiatric disorders like ADHD, Huntington’s disease, Parkinson’s disease, and dementia.

Carlsson Research, the originator of ACR-16, has gone through Phase Ia, as well as Phase Ib trial program in schizophrenia, Parkinson’s disease and Huntington’s disease. Those studies showed a favorable profile with respect to efficacy, safety and pharmacokinetics. Fujisawa will start development of ACR-16 for the treatment of schizophrenia. Carlsson Research retains rights to develop and market ACR-16 for the treatment of Huntington’s disease in specific countries.

A. CARLSSON RESEARCH AB is a pharmaceutical R&D company headquartered in Gothenburg, Sweden. Carlsson Research was founded by Prof. Em. Arvid Carlsson’s research group at Gothenburg University in 1998, focusing on new pharmacological treatment principles for neurologic and psychiatric disease.

#####